Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma

PURPOSE: We sought to compare the pharmacokinetics (PKs) of DRL-rituximab (DRL_RI; potential biosimilar) and innovator rituximab MabThera (Roche, Grenzach-Wyhlen, Germany; reference medicinal product [RMP]) in patients with diffuse large B-cell lymphoma (DLBCL). Efficacy, pharmacodynamics (PDs), saf...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Glob Oncol
Prif Awduron: Viswabandya, Auro, Shah, Sandip, Mukhopadhyay, Asis, Nagarkar, Rajnish Vasant, Batra, Sonica Sachdeva, Lopez-Lazaro, Luis, Kankanwadi, Suresh, Srivastava, Alok
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2019
Pynciau:
Original Reports
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6939748/
https://ncbi.nlm.nih.gov/pubmed/31809224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JGO.19.00248
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg